全球癌症免疫治療藥物市場：按治療類型、疾病類型、通路和地區分類

2025 年全球癌症免疫治療市場價值預估為 323.2 億美元，預計到 2032 年將達到 1,067.4 億美元，2025 年至 2032 年的複合年成長率為 18.6%。

數字。 2025 年癌症免疫治療藥物市場佔有率（%），按地區分類

免疫腫瘤藥物利用人體的免疫系統對抗癌症，並已被證明可以提高多種癌症類型的存活率。這些藥物可增強對癌細胞的免疫反應並提高存活率。目前主要核准的癌症免疫治療藥物類別包括查核點抑制劑、癌症疫苗和特異性免疫療法。持續的臨床研究和開發具有更高療效和安全性的新型藥物將推動市場成長。

市場動態：

全球免疫腫瘤藥物市場的成長主要受到全球癌症發生率上升的推動。由於生活方式的改變、壽命的延長以及污染等環境因素，癌症的發生率逐年上升。與傳統癌症治療方法相比，癌症免疫治療藥物已表現出更高的長期療效和存活率。這促進了藥品研發並增加了藥品核准。伴同性診斷的發展將透過確定最適合免疫療法的患者群體來推動市場成長。然而，這些藥物價格昂貴，這可能會限制其在價格敏感地區的採用。此外，免疫相關副作用等安全問題也可能阻礙市場成長。正在進行的評估新適應症、藥物組合和個人化治療的臨床試驗很可能在不久的將來為市場成長提供豐厚的機會。

本研究的主要特點

• 本報告對全球癌症免疫療法藥物市場進行了詳細分析，並以 2024 年為基準年，給出了預測期（2025-2032 年）的市場規模和復合年成長率。
• 它還強調了各個領域的潛在商機並解釋了該市場的有吸引力的投資提案矩陣。
• 它還提供了對市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景以及主要企業採用的競爭策略的重要見解。
• 全球免疫腫瘤藥物市場的主要企業已根據公司亮點、產品系列、關鍵亮點、財務績效和策略等參數進行了分析。
• 本報告的見解將使負責人和公司經營團隊能夠就未來的產品發布、類型升級、市場擴張和行銷策略做出明智的決策。
• 全球癌症免疫治療藥物市場報告針對該行業的各個相關人員，包括投資者、供應商、產品製造商、經銷商、新進業者和金融分析師。
• 相關人員可以透過分析全球免疫腫瘤藥物市場的各種策略矩陣來促進決策。

目錄

第1章 調查目的與前提條件

• 研究目標
• 先決條件
• 簡稱

第2章 市場展望

• 報告描述
  • 市場定義和範圍
• 執行摘要
• Coherent Opportunity Map（COM）

第3章市場動態、法規與趨勢分析

• 市場動態
  • 驅動程式
  • 限制因素
  • 機會
• 影響分析
• 市場趨勢
• 主要進展
• 監管情景
• 收購和合作場景
• 資金籌措和投資
• PEST分析
• 波特的分析

第 4 章全球癌症免疫治療市場：COVID-19 疫情的影響

• 整體影響
• 政府舉措
• COVID-19 市場影響

第 5 章。全球癌症免疫治療藥物市場按治療類型分類（2020-2032 年）

• 免疫查核點抑制劑
• PD-1
• PD-LI
• CTLA-4
• 免疫系統調節劑
• 癌症疫苗
• 溶瘤病毒
• 其他

第6章 全球癌症免疫治療藥物市場依疾病類型分類（2020-2032）

• 惡性黑色素瘤
• 肺癌
• 血癌
• 腎臟細胞癌
• 攝護腺癌
• 膀胱癌
• 其他

第7章 全球癌症免疫治療藥物市場依通路分類（2020-2032）

• 院內藥房
• 零售藥局
• 網路藥局

第 8 章 全球癌症免疫治療藥物市場按地區分類（2020 至 2032 年）

• 北美洲
• 拉丁美洲
• 歐洲
• 亞太地區
• 中東
• 非洲

第9章 競爭格局

• 公司簡介
  • Coloplast Corp
  • Bristol Myers Squibb Company
  • Novartis AG
  • F. Hoffmann-LA Roche Ltd.
  • Merck &Co., Inc.
  • GSK Plc.
  • Eli Lilly and Company
  • Fresenius Kabi AG
  • Pfizer Inc.
  • AbbVie Inc.
  • Genentech Inc.
  • Sanofi
  • AstraZeneca
  • Bayer AG
  • Bluebird Bio, Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Amgen Inc.

第 10 章分析師建議

• 命運之輪
• 分析師觀點
• Coherent Opportunity Map（COM）

第 11 章 參考文獻與調查方法

• 參考
• 調查方法

Global Immuno-oncology Drugs Market is estimated to be valued at USD 32.32 Bn in 2025 and is expected to reach USD 106.74 Bn by 2032, growing at a compound annual growth rate (CAGR) of 18.6% from 2025 to 2032.

Figure. Immuno-oncology Drugs Market Share (%), By Region 2025

Immuno-oncology drugs use the body's immune system to fight cancer, and have demonstrated improved survival rates for various cancer types. These drugs boost the immune response against cancer cells, and thus, improve survival outcomes. Some major immuno-oncology drug classes approved include checkpoint inhibitors, cancer vaccines, and nonspecific immunotherapies. Continued clinical research and development of novel agents with improved efficacy and safety profiles can drive the market growth.

Market Dynamics:

Global immuno-oncology drugs market growth is primarily driven by rising cases of cancer worldwide. Cancer incidence has been rising year-on-year owing to lifestyle changes, increased life expectancy, and environmental factors like pollution. Immuno-oncology drugs have demonstrated long-term efficacy and survival benefits as compared to conventional cancer therapies. This boosts pharmaceutical R&D and increases drug approvals. The developments in companion diagnostics identify patient populations most suitable for immunotherapies, thus, driving the market growth. However, high costs of these drugs can restrict its adoption in price-sensitive regions. Safety issues like immune-related adverse effects can also hamper the market growth. Ongoing clinical trials evaluating new indications, drug combinations, and personalized therapies can offer lucrative opportunities for the market growth in the near future.

Key Features of the Study:

• This report provides in-depth analysis of the global immuno-oncology drugs market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global immuno-oncology drugs market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Bristol-Myers Squibb, Merck, Roche, Pfizer, AstraZeneca, and Novartis
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• Global immuno-oncology drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global immuno-oncology drugs market

Detailed Segmentation-

• By Treatment Type
  • Immune Checkpoint Inhibitors
  • PD-1
  • PD-LI
  • CTLA-4
  • Immune System Modulators
  • Cancer Vaccines
  • Oncolytic Virus
  • Others
• By Disease Type
  • Melanoma
  • Lung Cancer
  • Blood Cancer
  • Renal Cell Carcinoma
  • Prostate Cancer
  • Bladder Cancer
  • Others (Breast Cancer, Thyroid Cancer, etc.)
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Region:
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa
• Company Profiles:
  • Coloplast Corp
  • Bristol Myers Squibb Company
  • Novartis AG
  • F. Hoffmann-LA Roche Ltd.
  • Merck & Co., Inc.
  • GSK Plc.
  • Eli Lilly and Company
  • Fresenius Kabi AG
  • Pfizer Inc.
  • AbbVie Inc.
  • Genentech Inc.
  • Sanofi
  • AstraZeneca
  • Bayer AG
  • Bluebird Bio, Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Amgen Inc.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Treatment Type
  • Market Snapshot, By Disease Type
  • Market Snapshot, By Distribution Channel
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Opportunities
• Impact Analysis
• Market Trends
• Key Developments
• Regulatory Scenario
• Acquisitions and Partnerships Scenario
• Funding and Investments
• PEST Analysis
• Porter's Analysis

4. Global Immuno-oncology Drugs Market - Impact of Coronavirus (COVID-19) Pandemic

• Overall Impact
• Government Initiatives
• COVID-19 Impact on the Market

5. Global Immuno-oncology Drugs Market, By Treatment Type, 2020 - 2032, (USD Bn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Immune Checkpoint Inhibitors
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• PD-1
• PD-LI
• CTLA-4
• Immune System Modulators
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Cancer Vaccines
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Oncolytic Virus
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Global Immuno-oncology Drugs Market, By Disease Type, 2020 - 2032, (USD Bn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Melanoma
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Lung Cancer
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Blood Cancer
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Renal Cell Carcinoma
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Prostate Cancer
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Bladder Cancer
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global Immuno-oncology Drugs Market, By Distribution Channel, 2020 - 2032, (USD Bn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Hospital Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Retail Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Online Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

8. Global Immuno-oncology Drugs Market, By Region, 2020 - 2032, (USD Bn)

• Introduction
  • Market Share Analysis, By Region, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, For Region, 2021-2032
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • GCC
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Sub-region, 2020 - 2032, (USD Bn)
    • North Africa
    • Central Africa
    • South Africa

9. Competitive Landscape

• Company Profiles
  • Coloplast Corp
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Bristol Myers Squibb Company
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Novartis AG
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • F. Hoffmann-LA Roche Ltd.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Merck & Co., Inc.
  • GSK Plc.
  • Eli Lilly and Company
  • Fresenius Kabi AG
  • Pfizer Inc.
  • AbbVie Inc.
  • Genentech Inc.
  • Sanofi
  • AstraZeneca
  • Bayer AG
  • Bluebird Bio, Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Amgen Inc.

10. Analyst Recommendation

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

11. References and Research Methodology

• References
• Research Methodology
• About Us and Sales Contact